|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ANLN |
Gene summary for ANLN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ANLN | Gene ID | 54443 |
| Gene name | anillin actin binding protein | |
| Gene Alias | FSGS8 | |
| Cytomap | 7p14.2 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q9NQW6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54443 | ANLN | LZE2T | Human | Esophagus | ESCC | 9.54e-06 | 7.69e-01 | 0.082 |
| 54443 | ANLN | LZE4T | Human | Esophagus | ESCC | 1.70e-03 | 2.71e-01 | 0.0811 |
| 54443 | ANLN | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 3.80e-01 | 0.068 |
| 54443 | ANLN | LZE21T | Human | Esophagus | ESCC | 1.37e-06 | 5.57e-01 | 0.0655 |
| 54443 | ANLN | P2T-E | Human | Esophagus | ESCC | 7.08e-13 | 4.74e-01 | 0.1177 |
| 54443 | ANLN | P4T-E | Human | Esophagus | ESCC | 4.13e-17 | 4.77e-01 | 0.1323 |
| 54443 | ANLN | P5T-E | Human | Esophagus | ESCC | 3.28e-28 | 7.00e-01 | 0.1327 |
| 54443 | ANLN | P9T-E | Human | Esophagus | ESCC | 3.05e-07 | 2.99e-01 | 0.1131 |
| 54443 | ANLN | P10T-E | Human | Esophagus | ESCC | 7.37e-10 | 4.07e-01 | 0.116 |
| 54443 | ANLN | P11T-E | Human | Esophagus | ESCC | 9.07e-04 | 3.53e-01 | 0.1426 |
| 54443 | ANLN | P12T-E | Human | Esophagus | ESCC | 2.20e-13 | 3.13e-01 | 0.1122 |
| 54443 | ANLN | P15T-E | Human | Esophagus | ESCC | 7.07e-10 | 3.17e-01 | 0.1149 |
| 54443 | ANLN | P16T-E | Human | Esophagus | ESCC | 2.04e-04 | 1.98e-01 | 0.1153 |
| 54443 | ANLN | P17T-E | Human | Esophagus | ESCC | 1.49e-05 | 5.38e-01 | 0.1278 |
| 54443 | ANLN | P19T-E | Human | Esophagus | ESCC | 6.53e-04 | 4.54e-01 | 0.1662 |
| 54443 | ANLN | P20T-E | Human | Esophagus | ESCC | 8.24e-04 | 1.56e-01 | 0.1124 |
| 54443 | ANLN | P21T-E | Human | Esophagus | ESCC | 1.29e-11 | 6.66e-01 | 0.1617 |
| 54443 | ANLN | P22T-E | Human | Esophagus | ESCC | 1.16e-05 | 3.34e-01 | 0.1236 |
| 54443 | ANLN | P23T-E | Human | Esophagus | ESCC | 1.83e-07 | 3.85e-01 | 0.108 |
| 54443 | ANLN | P24T-E | Human | Esophagus | ESCC | 4.09e-07 | 2.61e-01 | 0.1287 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:000028115 | Esophagus | ESCC | mitotic cytokinesis | 58/8552 | 71/18723 | 4.34e-10 | 1.15e-08 | 58 |
| GO:003250614 | Esophagus | ESCC | cytokinetic process | 35/8552 | 39/18723 | 9.38e-09 | 1.90e-07 | 35 |
| GO:000091016 | Esophagus | ESCC | cytokinesis | 115/8552 | 173/18723 | 2.48e-08 | 4.68e-07 | 115 |
| GO:006164015 | Esophagus | ESCC | cytoskeleton-dependent cytokinesis | 72/8552 | 100/18723 | 8.10e-08 | 1.39e-06 | 72 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:003086517 | Esophagus | ESCC | cortical cytoskeleton organization | 44/8552 | 61/18723 | 2.50e-05 | 2.13e-04 | 44 |
| GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
| GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
| GO:01200347 | Esophagus | ESCC | positive regulation of plasma membrane bounded cell projection assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
| GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
| GO:003086610 | Esophagus | ESCC | cortical actin cytoskeleton organization | 28/8552 | 40/18723 | 1.61e-03 | 7.50e-03 | 28 |
| GO:003103219 | Esophagus | ESCC | actomyosin structure organization | 108/8552 | 196/18723 | 4.86e-03 | 1.88e-02 | 108 |
| GO:001063120 | Esophagus | ESCC | epithelial cell migration | 187/8552 | 357/18723 | 6.05e-03 | 2.23e-02 | 187 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ANLN | SNV | Missense_Mutation | c.461G>C | p.Arg154Pro | p.R154P | Q9NQW6 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| ANLN | SNV | Missense_Mutation | c.2752A>T | p.Ser918Cys | p.S918C | Q9NQW6 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ANLN | SNV | Missense_Mutation | novel | c.1971N>T | p.Glu657Asp | p.E657D | Q9NQW6 | protein_coding | tolerated(0.15) | benign(0.078) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
| ANLN | SNV | Missense_Mutation | novel | c.1971N>T | p.Glu657Asp | p.E657D | Q9NQW6 | protein_coding | tolerated(0.15) | benign(0.078) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ANLN | SNV | Missense_Mutation | rs756975220 | c.932N>A | p.Gly311Glu | p.G311E | Q9NQW6 | protein_coding | tolerated(1) | benign(0.03) | TCGA-AR-A5QN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| ANLN | SNV | Missense_Mutation | novel | c.2761N>T | p.His921Tyr | p.H921Y | Q9NQW6 | protein_coding | tolerated(0.71) | benign(0) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ANLN | SNV | Missense_Mutation | novel | c.886N>T | p.Pro296Ser | p.P296S | Q9NQW6 | protein_coding | tolerated(0.1) | benign(0.424) | TCGA-LL-A5YN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| ANLN | insertion | Frame_Shift_Ins | novel | c.1055_1056insCTCTCCAAATGAAGTAACTATGCAGAAAAACATTTGG | p.Cys353SerfsTer19 | p.C353Sfs*19 | Q9NQW6 | protein_coding | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| ANLN | insertion | Frame_Shift_Ins | novel | c.1969_1970insCAGTT | p.Glu657AlafsTer35 | p.E657Afs*35 | Q9NQW6 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| ANLN | insertion | Frame_Shift_Ins | novel | c.1969_1970insCAGTT | p.Glu657AlafsTer35 | p.E657Afs*35 | Q9NQW6 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |